Home › Compare › EXSPF vs ABBV
EXSPF yields 99.50% · ABBV yields 3.06%● Live data
📍 EXSPF pulled ahead of the other in Year 1
Combined, EXSPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EXSPF + ABBV for your $10,000?
Expert.ai S.p.A., an artificial intelligence (AI) platform company, develops and sells cognitive computing software products based on AI algorithms to read and understand written language worldwide. The company offers expert.ai Platform that captures the strategic value of language data; expert.ai Answers, a customer support automation software that allows human like interaction between customers and internal staff, using the language of business and users; expert.ai Discover, a text analytics, and extraction and categorization software; expert.ai for Insurance that automate insurance claims management with natural language understanding; and expert.ai for Life Sciences to mimic the human like comprehension of scientific content, such as publications, patents, clinical trials, or medical reports. It serves the banking and insurance, public administration, life science and pharma, oil and gas, media and publishing, and telecom and utilities industries, as well as defense, and intelligence and law enforcement industries. Expert.ai S.p.A. has a strategic partnership agreement with WealthIntel Inc. to facilitate innovations in natural language and text analytics. The company was formerly known as Expert System S.p.A. and changed its name to Expert.ai S.p.A. in May 2021. Expert.ai S.p.A. was founded in 1989 and is headquartered in Modena, Italy.
Full EXSPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.